• Services
    • Infusion Management Services Navigation Header
      • Infusion Management Services
    • Ambulatory Infusion Centers Header
      • Ambulatory Infusion Centers
    • Pharmacy Services Navigation Header
      • Pharmacy Services
    • Wholesale Distribution Navigation Header
      • Wholesale Distribution
    • Clinical Outcomes Research Navigation Header
      • Clinical Outcomes Research
    • Outsourced Patient Support and Hub Services Navigation Header
      • Outsourced Patient Support and Hub Services
  • Company
    • About Us
    • News & Events
    • History of Infusion
  • Careers
  • Contact Us
  • Contact Us
  • Services
    • Infusion Management Services
    • Ambulatory Infusion Centers
    • Pharmacy Services
    • Wholesale Distribution
    • Clinical Outcomes Research
    • Outsourced Patient Support and Hub Services
  • Company
    • About Us
    • News & Events
    • History of Infusion
  • Careers

Real-World Utilization of Immune Globulin Subcutaneous 16.5% in Treatment-Naïve Primary Immunodeficient Patients

Nov 14, 2022 | Clinical Outcomes

Presented at ACAAI 2022 Authors: Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Dawn N. Kim-Romo, PharmD, PhD Lucinda J. Van Anglen, PharmD View Poster

Real-World Utilization of Immune Globulin Intravenous 10% at Physician Office Infusion Centers

Nov 14, 2022 | Clinical Outcomes

Presented at ACAAI 2022 Authors: Richard F. Herrscher, MD, FACAAI Quyen Luu, MD Dawn N. Kim-Romo, PharmD, PhD Lucinda J. Van Anglen, PharmD View Poster

Recent Posts

  • Real-World Experience with Rezafungin: A Novel Long-Acting Echinocandin
  • Immune Globulin Subcutaneous 16.5% in Immunoglobulin-Naïve Patients with Primary Immunodeficiency
  • Effectiveness of A Community-based Inflammatory Bowel Disease Medical Home Compared to Patients not in a Medical Home
  • Real-world Effectiveness and Onset of Action of Vedolizumab as a First-line Biologic in Biologic-Naïve Patients With Ulcerative Colitis
  • Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency: A Two-Year, Multi-Center Analysis

Recent Comments

    Archives

    • April 2025
    • March 2025
    • February 2025
    • December 2024
    • October 2024
    • August 2024
    • May 2024
    • April 2024
    • February 2024
    • November 2023
    • October 2023
    • June 2023
    • February 2023
    • January 2023
    • November 2022
    • October 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • November 2021
    • October 2021
    • September 2021
    • November 2020
    • October 2020
    • July 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • February 2019
    • December 2018
    • October 2018
    • July 2018
    • June 2018
    • January 2018
    • December 2017
    • October 2017
    • July 2017
    • June 2017
    • March 2017
    • October 2016
    • June 2016
    • January 2016
    • October 2015
    • December 2014
    • October 2014
    • November 2013
    • October 2013
    • July 2013
    • February 2013
    • January 2013
    • December 2012
    • November 2012
    • October 2012
    • April 2012
    • February 2012
    • January 2012
    • October 2011
    • January 2011
    • October 2010
    • October 2009
    • October 2008

    Categories

    • Blog
    • Clinical Outcomes
    • Cost Savings
    • Events
    • Infusion Management Services
    • New Therapies & Programs
    • News
    • Persistence
    • Services
    • Special Populations

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Follow
    • Follow
    • Follow
    • Contact Us
    • Careers
    • Terms and Conditions
    • Privacy Policy
    • Client Login

    2150 Town Square Place Suite 395, Sugar Land, TX  77479
    (800)-422-2204

    © Healix Infusion Therapy